SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, today announced unaudited financial results for the three and six month periods ended June 30, 2007.
